Alnylam Pharmaceuticals, Inc. has entered into a $500 million revolving credit agreement with Bank of America on September 30, 2025, for working capital and general corporate purposes. The agreement allows incremental loans and features a minimum interest coverage ratio and leverage ratio requirements.